Know Cancer

forgot password

Phase II Trial of Accelerated Fraction Radiotherapy With Concomitant Capecitabine as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer

Phase 2
18 Years
Open (Enrolling)
Pancreatic Cancer

Thank you

Trial Information

Phase II Trial of Accelerated Fraction Radiotherapy With Concomitant Capecitabine as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer

Inclusion Criteria


1. Clinically staged I-III, pathologically confirmed adenocarcinoma of the pancreas.
Mixed (e.g. adeno-squamous, neuroendocrine features) and/or poorly differentiated
carcinomas are eligible as long as the carcinoma is not a predominantly
neuroendocrine carcinoma. Cancers must be deemed by multidisciplinary assessment at
UVA to be either

- Resectable

- No overt evidence of vascular involvement

- No overt metastatic disease

- Borderline Resectable, meeting one of the following categories:

- Local tumor characteristics:

- Abutment of <180◦ of the superior mesenteric artery and/or celiac

- Abutment or encasement of a short segment hepatic artery

- Involvement of the portal vein or superior mesenteric vein amenable to
vascular reconstruction

- Concern for extra pancreatic metastatic disease

- indeterminant nodule on imaging

- Pathologically confirmed N1

- Borderline performance status or medical comorbidities as determined by
investigators to be concerning for patient's ability to tolerate pancreatic

- Patients with overtly unresectable disease are ineligible

2. No prior therapy for pancreatic cancer, including surgery, radiation, or chemotherapy

3. ≥18 years of age

4. Able to provide informed consent and comply with study procedures

5. Concurrent therapy with warfarin is permitted, but INR must be checked weekly

6. Concurrent therapy with phenytoin is permitted, but phenytoin levels must be checked

7. Concurrent therapy with CYP2C9 substrates is permitted but discouraged. Patients
taking fluoxetine, glipizide, losartan, voriconazole, or other CYP2C9 substrates
should consider switching to an alternative medication if feasible. (see Appendix
11.3 for a list of CYP2C9 substrates).

8. Adequate organ function:

- Hematologic

- ANC ≥ 1.5 x 10^9 cells/liter

- Plts ≥ 100,000 x 10^9 cells/liter

- Hepatic

- Total bilirubin ≤ 5 fold the upper limits of normal for laboratory if due
to biliary obstruction secondary to disease. For patients with total
bilirubin 3-5 times the upper limit, attempt to relieve biliary obstruction
is required

- AST/ALT ≤ 5 fold the upper limits of normal for laboratory

- Renal

- Creatinine clearance as measured by Cockcroft-Gault (APPENDIX) of >30

- Patients with creatinine clearance of 30-50 mL/min require 25% reduction of
capecitabine dose.


1. No pregnant or lactating women. Women of child bearing age must have a negative
pregnancy test within seven days of beginning therapy and agree to use reliable
contraception for the duration of the study period.

2. No comorbid condition which is deemed by the investigator to have a life expectancy
of less than 6 months

3. No other malignancy diagnosed within the past 5 years, excepting all in situ cancers
and invasive nonmelanomatous skin cancers.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the safety of neoadjuvant accelerated fraction standard dose radiotherapy to 50 Gy with concomitant capecitabine in patients with resectable and borderline resectable pancreas cancer.

Outcome Time Frame:

2 years

Safety Issue:



United States: Institutional Review Board

Study ID:




Start Date:

August 2010

Completion Date:

Related Keywords:

  • Pancreatic Cancer
  • Pancreas
  • Radiation
  • Pancreatic Neoplasms



University of Virginia Charlottesville, Virginia  22908